RU2013148601A

RU2013148601A - METHOD FOR PHOTODYNAMIC THERAPY OF ONCOLOGICAL DISEASES

Info

Publication number: RU2013148601A
Application number: RU2013148601/14A
Authority: RU
Inventors: Татьяна Владимировна Сергеева; Евгений Валерьевич Жаров; Оскар Иосифович Койфман; Олег Павлович Богатырев; Виктория Викторовна Базаева; Алексей Владимирович Луковкин; Гелий Васильевич Пономарев
Original assignee: Евгений Валерьевич Жаров
Priority date: 2013-10-31
Filing date: 2013-10-31
Publication date: 2015-05-10

Abstract

1. Способ фотодинамической терапии онкологических заболевания, включающий введение фотосенсибилизатора в зону опухолевой ткани, воздействие на опухолевую ткань ИК-лазерным излучением, отличающийся тем, что в качестве фотосенсибилизатора вводят композицию из 5,10,15,20-тетракис(N-метил-3′-пиридил)хлорина и 5,10,15,20-тетракис(N-метил-3′-пиридил)бактериохлорина в объеме 0,5-10 мг на 1 г опухолевой ткани в зависимости от дифференцировки опухоли, а лазерное воздействие осуществляют через 20-40 мин, через 6-7 дней проводят цитологические исследования и при выявлении признаков продолжающегося опухолевого роста полностью повторяют сеанс предлагаемого лечения.2. Способ по п.1, отличающийся тем, что при высокодифференцированных формах опухоли вводят 0,5-2 мг фотосенсибилизатора на 1 г опухолевой ткани.3. Способ по п.1, отличающийся тем, что при опухолевой ткани с признаками снижения дифференцировки вводят 2-5 мг фотосенсибилизатора на 1 г опухолевой ткани.4. Способ по п.1, отличающийся тем, что при видах опухолей с недифференцированной формой опухоли или при гемобластозах вводят не менее 5-10 мг фотосенсибилизатора на 1 г опухолевой ткани.1. The method of photodynamic therapy of cancer, including the introduction of a photosensitizer into the area of the tumor tissue, the impact on the tumor tissue with IR laser radiation, characterized in that as a photosensitizer is administered a composition of 5,10,15,20-tetrakis (N-methyl-3 ′ -Pyridyl) chlorin and 5,10,15,20-tetrakis (N-methyl-3′-pyridyl) bacteriochlorin in a volume of 0.5-10 mg per 1 g of tumor tissue, depending on the differentiation of the tumor, and laser exposure is carried out through 20-40 minutes, after 6-7 days, cytological studies are carried out and at Identification of signs of ongoing tumor growth completely repeat the session of the proposed treatment. 2. The method according to claim 1, characterized in that with highly differentiated forms of the tumor, 0.5-2 mg of a photosensitizer per 1 g of tumor tissue is administered. The method according to claim 1, characterized in that in case of tumor tissue with signs of reduced differentiation, 2-5 mg of photosensitizer per 1 g of tumor tissue is administered. The method according to claim 1, characterized in that for types of tumors with an undifferentiated form of the tumor or for hemoblastoses, at least 5-10 mg of a photosensitizer per 1 g of tumor tissue is administered.

Claims

1. The method of photodynamic therapy of cancer, including the introduction of a photosensitizer into the area of the tumor tissue, the impact on the tumor tissue with IR laser radiation, characterized in that as a photosensitizer is administered a composition of 5,10,15,20-tetrakis (N-methyl-3 ′ -Pyridyl) chlorin and 5,10,15,20-tetrakis (N-methyl-3′-pyridyl) bacteriochlorin in a volume of 0.5-10 mg per 1 g of tumor tissue, depending on the differentiation of the tumor, and laser exposure is carried out through 20-40 minutes, after 6-7 days, cytological studies are carried out and at Identification of signs of ongoing tumor growth completely repeat the session of the proposed treatment.

2. The method according to claim 1, characterized in that with highly differentiated forms of the tumor, 0.5-2 mg of a photosensitizer per 1 g of tumor tissue is administered.

3. The method according to claim 1, characterized in that with tumor tissue with signs of reduced differentiation, 2-5 mg of photosensitizer per 1 g of tumor tissue is administered.

4. The method according to claim 1, characterized in that for types of tumors with an undifferentiated form of the tumor or for hemoblastoses, at least 5-10 mg of a photosensitizer per 1 g of tumor tissue is administered.